The effects of nitrogen deficiencies on the lipid and protein contents of Spirulina platensis

Nitrogen deficiencies were studied in Spirulina platensis (Cyanophyceae) with the aim of determining the effects of the 50 and 100% deficient nitrogen on the lipid and protein contents of the cell under laboratory conditions. S. platensis cultures were grown in Spirulina medium and kept at the constantroom temperature of 26 ± 2°C, illuminated with fluorescent lamps at an irradiance level of 80 ìmol m-2 s-1 with photoperiod 16:8 (L:D) and aerated continuously. In the Spirulina biomass harvested at the stationary phase, 67.4, 53.5, 5.6% protein and 5.78, 13.66, 17.05% lipid were recorded for the groups of control, 50% N(-) and 100% N(-), respectively. The highest lipid content and 1.00 gL-1 dry-weight were recorded from the culture to which treated 100% N(-).Key words: Spirulina platensis, lipid, nitrogen deficiencies, protein

The effects of nitrogen and phosphorus deficiencies and nitrite addition on the lipid content of Chlorella vulgaris (Chlorophyceae)

The effect of 50% N, 100% N, 50% N plus 50% P and 50% P deficiencies and nitrite addition were treated on Chlorella vulgaris (Chlorophyceae) was studied in laboratory conditions with the aim to determine the effects of the deficient nutrient and different nitrogen sources on lipid and protein contents. Proteinand lipid values of the biomass were found as 50.8 and 12.29% for the control group, 20.3 and 17.5% for 50% N(-), 13.01 and 35.6% for 100% N(-), 21.37 and 20.5% for 50% N(-) and 50% P(-), 38.16 and 16.7% for 50% P(-) and 41.03 and 13.04% for the nitrite group that was added. The highest lipid content was recorded with the culture to which 100% N(-) was treated with 0.18 g/L dry-weight.Key words: Chlorella vulgaris, lipid, nitrogen and phosphorus deficiencies, nitrite

L-MYC gene polymorphism and risk of thyroid cancer

L-myc gene polymorphism is a representative genetic trait responsible for an individual’s susceptibility to several cancers. However, there have been no reports concerning the association between thyroid cancer and L-myc gene polymorphism. Aim: To analyze the distribution of L-myc gene polymorphism in Turkish patients with thyroid disorders and thyroid cancers. Methods: We used a molecular genotyping method, polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP). We studied 138 patients of whom 47 had multinodular goiter, 13 had follicular cancer and 69 had papillar cancer, in comparison with control group of 109 healthy individuals. Results: No significant difference in the distribution of genotypes was observed between thyroid patients and controls. Carrying SS or LS genotype revealed a 1.96-fold (95% CI 0.573–6.706) risk for the occurrence of follicular cancer when compared with controls, and 3.11-fold (95% CI 0.952–10.216), when compared with multinodular goiter patients (p = 0.04). Conclusion: We suggest that L-myc genotype profiling together with other susceptibility factors, may be useful in the screening for thyroid nodular malignancy.Для ряда опухолей человека показана корреляция между риском развития опухоли и определенным вариантом гена L-MYC. Данные о наличии такой связи при раке щитовидной железы к настоящему времени отсутствуют. Цель: проанализировать распределение полиморфных типов гена L-MYC в популяции больных с доброкачественными и злокачественными поражениями щитовидной железы, включая рак щитовидной железы, в Турции. Методы: для анализа полиморфизма гена L-MYC использован метод молекулярного генотипирования, в частности, метод определения полиморфизма длины рестрикционных фрагментов, основанный на полимеразной цепной реакции (PCR-RFLP). Определение проводили в лейкоцитах 138 больных, в том числе 48 больных с узловым зобом, 13 больных фолликулярным раком щитовидной железы и 69 больных папиллярным раком. Контрольную группу составляли 109 здоровых лиц. Результаты: статистически достоверных различий в распределении исследуемых генотипов у больных с патологией щитовидной железы и здоровых лиц не выявили. Показано, что относительный риск фолликулярного рака щитовидной железы у больных-носителей генотипа SS или LS составляет 1,96 по сравнению со здоровыми лицами (при 95% доверительном интервале от 0,573 до 6,706) и 3,11 по сравнению с больными с узловым зобом (при 95% доверительном интервале от 0,952 до 10,216) (р = 0,04). Выводы: по нашему предположению, определение профиля полиморфизма гена L-MYC с учетом других факторов, определяющих предрасположенность к развитию опухолей, может быть полезным при скрининге озлокачествления узелковых образований щитовидной железы

Synthesis of Carboxymethyl Starch for increasing drilling mud quality in drilling oil and gas wells

This paper describes the impact of carboxymethyl starch preparation conditions on physicochemical properties of polysaccharide reagent, widely used as fluid loss reducing agent in drilling mud. Variation of the main parameters of carboxymethylation is researched in the experiment. The following conditions such as temperature and reaction time, amount of water, as well as ratio of NaOH to monochloracetic acid define the characteristics of carboxymethyl starch. The degree of substitution is defined for polysaccharides, as well as the characteristics of samples have been studied by infrared spectroscopy. Rheological characteristics and fluid loss indicator have been investigated to study the impact of the reagents on drilling mud quality

Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis

Treatment of the hormone refractory prostate cancer cell line DU 145 with sublethal concentrations of chemotherapeutic drugs has been reported to sensitise these cells to Fas mediated apoptosis. However, the mechanism by which this occurs has not been determined. Our group has shown that inhibition of JNK activity completely abrogates the effects of chemotherapeutic drugs. Using anisomycin, a potent JNK agonist, we have demonstrated a role for JNK in Fas mediated apoptosis in DU 145 cells. Inhibition of Caspase 8 and Caspase 9 completely inhibits this process which suggests that DU 145 cells require mitochondrial amplification of the Fas apoptotic signal. Furthermore, we have shown that inhibition of Fas mediated apoptosis is an early event in DU 145 cells, occurring upstream of Caspase 8 cleavage. It is hoped that identifying the target of JNK will allow novel therapies to be developed for the treatment of hormone refractory prostate cancer. Such therapies are especially important because no single or combined treatment to date has significantly prolonged survival in patients with hormone refractory prostate cancer

Guided self-help on the internet for turkish migrants with depression: the design of a randomized controlled trial

Background The Turkish population living in the Netherlands has a high prevalence of psychological complaints and has a high threshold for seeking professional help for these problems. Seeking help through the Internet can overcome these barriers. This project aims to evaluate the effectiveness of a guided self-help problem-solving intervention for depressed Turkish migrants that is culturally adapted and web-based. Methods This study is a randomized controlled trial with two arms: an experimental condition group and a wait list control group. The experimental condition obtains direct access to the guided web-based self-help intervention, which is based on Problem Solving Treatment (PST) and takes 6 weeks to complete. Turkish adults with mild to moderate depressive symptoms will be recruited from the general population and the participants can choose between a Turkish and a Dutch version. The primary outcome measure is the reduction of depressive symptoms, the secondary outcome measures are somatic symptoms, anxiety, acculturation, quality of life and satisfaction. Participants are assessed at baseline, post-test (6 weeks), and 4 months after baseline. Analysis will be conducted on the intention-to-treat sample. Discussion This study evaluates the effectiveness of a guided problem-solving intervention for Turkish adults living in the Netherlands that is culturally adapted and web-based

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

BACKGROUND: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. PATIENTS AND METHODS: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8\u2009mg/kg loading dose, then 6\u2009mg/kg every 3\u2009weeks (q3w)] and pertuzumab (840\u2009mg loading dose, then 420\u2009mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). RESULTS: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54\u2009years; 29% had received prior trastuzumab. Median treatment duration was 16\u2009months for pertuzumab and trastuzumab and 4\u2009months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months' median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1\u2009months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). CONCLUSIONS: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile. CLINICALTRIALS.GOV: NCT01572038

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. Patients and methods: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. Results: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade 653 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). Conclusions: Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design